



PRESS RELEASE

April 30, 2026 09:05:00 CEST

## Change in the number of shares and votes in Egetis Therapeutics

**Stockholm, Sweden, April 30, 2026.** The number of shares and votes in Egetis Therapeutics AB (publ) ("Egetis Therapeutics" or the "Company") (Nasdaq Stockholm: EGTX) has increased in the month of April as a result of the directed issue of 66,666,667 ordinary shares as announced on April 21, 2026.

The total number of shares in the Company has increased by 66,666,667, from 424,161,938 to 490,828,605, and the total number of votes in the Company has increased by 66,666,667, from 398,062,598.6 to 464,729,265.6. The share capital has increased by SEK 3,508,773.256327, from SEK 22,324,320.854470 to SEK 25,833,094.110797.

### For further information, please contact

---

Nicklas Westerholm, CEO  
nicklas.westerholm@egetis.com  
+46 (0) 733 542 062

Yilmaz Mahshid, CFO  
yilmaz.mahshid@egetis.com  
+46 (0) 722 316 800

Karl Hård, Head of Investor Relations & Business Development  
karl.hard@egetis.com  
+46 (0) 733 011 944

*This information is information that Egetis Therapeutics is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-04-30 09:05 CEST.*

## About Egetis Therapeutics

---

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Company's lead drug candidate Emcitate® (tiratricol) is developed for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In February 2025 the European Commission approved Emcitate® as the first and only treatment for MCT8 deficiency in EU. Egetis initiated the launch of Emcitate® in Germany on May 1, 2025. Emcitate® (tiratricol) is not approved in the USA.

On March 27, 2026, Egetis announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for Emcitate® (tiratricol) for the treatment of MCT8 deficiency. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date, or FDA decision date, of September 28, 2026.

The NDA for Emcitate® (tiratricol) for treatment of MCT8 deficiency is based on clinical data from Triac Trial I, Triac Trial II, ReTRIACt, EMC Cohort Study, EMC Survival Study and the US Expanded Access Program.

Tiratricol holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Tiratricol has been granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation (RPDD) by the FDA, which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval.

The drug candidate Aladote® (calmangafodipir) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb/III study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The development program for Aladote® has been parked. Aladote® has been granted ODD in the US and in the EU.

Egetis Therapeutics is listed on the Nasdaq Stockholm main market (Nasdaq Stockholm: EGTX).

For more information, see [www.egetis.com](http://www.egetis.com)

## Attachments

---

[Change in the number of shares and votes in Egetis Therapeutics](#)